Skip to Content
Merck
  • MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability.

MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability.

Molecular cancer (2017-03-09)
Francesca Mancini, Emanuela Teveroni, Giusy Di Conza, Valentina Monteleone, Ivan Arisi, Marsha Pellegrino, Marianna Buttarelli, Luisa Pieroni, Mara D'Onofrio, Andrea Urbani, Alfredo Pontecorvi, Massimiliano Mazzone, Fabiola Moretti
ABSTRACT

Many tumor-related factors have shown the ability to affect metabolic pathways by paving the way for cancer-specific metabolic features. Here, we investigate the regulation of mTORC1 by MDM4, a p53-inhibitor with oncogenic or anti-survival activities depending on cell growth conditions. MDM4-mTOR relationship was analysed through experiments of overexpression or silencing of endogenous proteins in cell culture and using purified proteins in vitro. Data were further confirmed in vivo using a transgenic mouse model overexpressing MDM4. Additionally, the Cancer Genome Atlas (TCGA) database (N = 356) was adopted to analyze the correlation between MDM4 and mTOR levels and 3D cultures were used to analyse the p53-independent activity of MDM4. Following nutrient deprivation, MDM4 impairs mTORC1 activity by binding and inhibiting the kinase mTOR, and contributing to maintain the cytosolic inactive pool of mTORC1. This function is independent of p53. Inhibition of mTORC1 by MDM4 results in reduced phosphorylation of the mTOR downstream target p70S6K1 both in vitro and in vivo in a MDM4-transgenic mouse. Consistently, MDM4 reduces cell size and proliferation, two features controlled by p70S6K1, and, importantly, inhibits mTORC1-mediated mammosphere formation. Noteworthy, MDM4 transcript levels are significantly reduced in breast tumors characterized by high mTOR levels. Overall, these data identify MDM4 as a nutrient-sensor able to inhibit mTORC1 and highlight its metabolism-related tumor-suppressing function.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human RPS6KB1
Sigma-Aldrich
Catalase from bovine liver, lyophilized powder, ≥10,000 units/mg protein